Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.76 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | DGKA | P23743 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.59 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28007041 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL18789084 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL27868394 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7769159 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL895900 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL18675509 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL28144472 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL18789083 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL18789085 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL27536946 | 1.00 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186074-A1 | LIPID VESICLES DERIVED FROM OLIVE OIL FATTY ACIDS | PAI HOLDINGS, LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186074-A1 | LIPID VESICLES DERIVED FROM OLIVE OIL FATTY ACIDS | PAI HOLDINGS, LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186074-A1 | LIPID VESICLES DERIVED FROM OLIVE OIL FATTY ACIDS | ELOVL3, LIPA, ACOX3 | PRKCA 1190/4885PRKCE 1116/4885PRKCQ 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.